RYR2 and breast carcinoma: A previous study found that ryanodine receptor isoform-2 (RYR2) gene expression was upregulated by 45-fold in epidermal growth factor (EGF)-treated MDA-MB-468 cells (mesenchymal-like state) compared to MDA-MB-468 cells (epithelial-like state), suggesting that the involvement of the RYR2/Ca2+ signalling pathway in the EGF-induced epithelial-mesenchymal transition (EMT) in breast cancer, which is a critical process for cell adhesion, invasion and migration, ultimately leads to a metastatic state [20].